DiaMedica Initiates Phase II Diabetes Trial
Posted on: Wednesday, 19 March 2008, 06:00 CDT
DiaMedica has enrolled the first patient in the Phase II proof of concept clinical trial of DM-83 for the treatment of type 2 diabetes.
Karl-Gunnar Hidinger, company's president said that the single-blind trial will demonstrate DM-83's level of effectiveness in controlling the blood glucose levels in twenty type 2 diabetics after they have consumed a meal. Changes in insulin and glucose levels are the study's primary endpoints. Each patient will test both the effects of DM-83 as well as a placebo and therefore serve as their own control in this crossover study. Treatment will be concluded in the second quarter and results will be analyzed and released shortly thereafter. The results of this trial will be used to optimize the design of the next stage of clinical development for DM-83.
Mr Hidinger, said: "We have discovered a very unique approach to treating this disease and believe we have found something quite important, as indicated by the clinical growth of our drug pipeline over the past six months."
Source: Datamonitor
Related Articles
- The NCI-Funded Standardized Expression Measurement (SEM) Center(TM) Based on StaRT-PCR(TM) Enables Multi-Institutional Clinical Trials and Facilitates Development of Drugs and Molecular Diagnostic Tests
- Clinical Trials Update:&Nbsp;Oct. 25, 2004
- Phase III Study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19
- Clinical Trials Update:&Nbsp;Oct. 21, 2004
- Clinical Trials Update:&Nbsp;Oct. 18, 2004
- The Challenges of Validating Diagnostic Methods Relative to a Conventional Two-Year Caries Clinical Trial
- Clinical Trial Results May Boost ImClone
- Clinical Trials Update: Mar. 11, 2003
- Clinical Trials Update: Mar. 5, 2003
- Clinical Trials Update: Jan. 27, 2003
 |
 |
User Comments (0)
RSS Feeds